Terms ending in 2037
Every in-force patent on Atea Pharmaceuticals, Inc.'s record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,202,412 | BETA-D-2'-Deoxy-2'-Substituted-4'-Substituted-2-Substituted-N6-SUBSTITUTED-6-Aminopurinenucleotides for the Treatment of Paramyxovirus and Orthomyxovirus Infections In force · Medium confidence | Atea Pharmaceuticals, Inc. | In force | Medium confidence | |
| US 10,711,029 | BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-4'-Fluoro-N6-SUBSTITUTED-6-Amino-2-Substituted Purine Nucleotides for the Treatment of Hepatitis C Virus Infection In force · High confidence | Atea Pharmaceuticals, Inc. | In force | High confidence | |
| US 10,946,033 | 2'-Substituted-N6-SUBSTITUTED Purine Nucleotides for RNA Virus Treatment In force · Medium confidence | Atea Pharmaceuticals, Inc. | In force | Medium confidence | |
| US 11,975,016 | 2'-Substituted-N6-SUBSTITUTED Purine Nucleotides for RNA Virus Treatment In force · Low confidence | Atea Pharmaceuticals, Inc. | In force | Low confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.